IMMEDIATE AND LONG-TERM OUTCOMES OF DRUG TREATMENT IN PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER
https://doi.org/10.18027/2224-5057-2018-8-3-68-77
Abstract
Triple-negative breast cancer (TNBC) comprises 12–20 % of all breast cancers. TNBC is defined by the absence of estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) expression. TNBC is a heterogeneous disease, with an aggressive clinical feature, a higher risk of both local and distant visceral and / or brain metastases. Recurrence usually develops between 1 and 3 years after the initial diagnosis and most deaths occur within 5 years. Epidemiologic studies illustrate a high prevalence of triple-negative breast cancers among young women. Triple-negative breast cancer is also more likely to occur in women that carry a BRCA mutation, especially if they are diagnosed at a young age. Cytotoxic chemotherapy remains the mainstay treatment for TNBC because there are currently no specific targets for treatment options (hormone receptors or HER-2 amplification). Chemotherapy combined with targeted agents including DNA repair with PARP inhibitors, EGFR inhibitors, anti-angiogenic agents and a Chk1 inhibitor produced modest improvement in response rate and overall survival. Nevertheless there’s no common standards for treatment such patients with metastatic TNBC. Progress in the development of new regimens and combination of drug treatment agents for patient with generalized TNBC remains an important challenge that could lead to improvement immediate and long-term outcomes.
About the Authors
O. V. Smirmova
Moscow Oncological Clinical Dispensary No. 1; A. I. Yevdokimov Moscow State University of Medicine and Denistry.
Russian Federation
Russian Federation
Olga V. Smirnova, oncologist, Chemotherapy Department; MD, PhD student, Department of Oncology and Radiology.
Moscow.
V. I. Borisov
Moscow Oncological Clinical Dispensary No. 1.
Russian Federation
Russian Federation
Vasiliy I. Borisov, MD, DSc Med, Professor, Head of the Outpatient Clinic.
Moscow.
G. P. Guens
A. I. Yevdokimov Moscow State University of Medicine and Denistry.
Russian Federation
Russian Federation
Gelena P. Guens, MD, DSc Med, Professor, Head of the Department of Oncology and Radiology.
Moscow.
References
1. DeSantis C., Ma J., Bryan L. et al. Breast cancer statistics, 2013. CA Cancer. J. Clin. 2014. Vol. 64. P. 52–62.
2. DeSantis C. E., Bray F., Ferlay J. et al. International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol. Biomarkers Prev. 2015. Vol. 24. P. 1495–1506.
3. Чиссов В. И., Дарьялова С. Л. Онкология. М.: ГЭОТАР-Медиа, 2009. C. 38–43. [Chissov V. I., Dar’yalova S. L. Onkologiya (Oncology). Moscow: GEOTAR-Media, 2009. P. 38–43 (In Russ.)].
4. Perou C. M. Molecular stratification of triple-negative breast cancer. J. Oncologist. 2010. Vol. 15 (5). P. 39–48.
5. Carey L. A. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006. Vol. 295. P. 2492–2502.
6. Nielsen T. O., Hsu F. D., Jensen K. et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clinical Cancer Research. 2004. Vol. 10 (16). P. 5367–5374.
7. Carey L. A., Dees E. C., Sawyer L. et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 2007. Vol. 13. P. 2329–2334.
8. Chavez K. J., Garimella S. V., Lipkowitz S. Triple negative breast cancer cell lines: one tool in search for better treatment of triple negative breast cancer. Breast Dis. 2010. Vol. 32 (1–2). P. 35–48.
9. Miller K., Wang M., Gralow J. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New EnglandJ. Medicine. 2007. Vol. 357 (26). P. 2666–2676.
10. Miles D. W., Chan A., Dirix L. Y. et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2‑negative metastatic breast cancer. J. Clinical Oncology. 2010. Vol. 28 (20). P. 3239–3247.
11. Linderholm B. K., Hellborg H., Johansson U. et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Annals of Oncology. 2009. Vol. 20 (10). P. 1639–1646.
12. Zhang J., Wang L., Wang Z., Hu X., Wang B., Cao J. et al. A phase II trial of biweekly vinorelbine and oxaliplatin in second- or thirdline metastatic triple-negative breast cancer. Cancer Biol. Ther. 2015. Vol. 16 (2). P. 225–232. DOI: 10.4161/15384047.2014.986973.
13. Liu J., Xiao Y., Wei W., Guo J., Liu Y., Huang X. N. et al. Clinical efficacy of administering oxaliplatin combined with S-1 in the treatment of advanced triple-negative breast cancer. Exp. Ther. Med. 2015. Vol. 10 (1). P. 379‑385. DOI: 10.3892/etm.2015.2489.
14. Kang M., Jiang H., Wang S. et al. Efficacy of docetaxel combined with oxaliplatin by different administration routes in treatment of anthracycline-resistant metastatic breast cancer. Zhong Guo Zhong Liu Lin Chuang Yu Kang Fu. 2005. Vol. 12. P. 527–529.
Review
For citations:
Smirmova O.V., Borisov V.I., Guens G.P. IMMEDIATE AND LONG-TERM OUTCOMES OF DRUG TREATMENT IN PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER. Malignant tumours. 2018;8(3):68-77. (In Russ.) https://doi.org/10.18027/2224-5057-2018-8-3-68-77
Views:
8501
Email this article 